Viking Therapeutics (VKTX) News Today $27.43 +0.42 (+1.55%) As of 12:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Cantor Fitzgerald L. P. Takes $380,000 Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)Cantor Fitzgerald L. P. bought a new position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 9,450 shares of the biotechnoMay 7 at 6:53 AM | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Shares Sold by Bamco Inc. NYBamco Inc. NY decreased its position in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 18.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 385,472 shares of the biotechnology company's stocMay 7 at 5:58 AM | marketbeat.comAQR Capital Management LLC Boosts Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)AQR Capital Management LLC increased its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 15.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 537,239 shares of the biotechnolMay 6 at 4:47 AM | marketbeat.comWhy Viking Therapeutics Stock Surged Nearly 20% Higher in AprilMay 6 at 4:33 AM | fool.comApis Capital Advisors LLC Has $3.86 Million Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)Apis Capital Advisors LLC raised its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 24.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 96,000 shares of the biotechnology company's stock afteMay 5 at 7:43 AM | marketbeat.com5AM Venture Management LLC Has $7.63 Million Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)5AM Venture Management LLC cut its position in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 20.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 189,593 shares of the biotMay 4 at 7:15 AM | marketbeat.com683 Capital Management LLC Lowers Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)683 Capital Management LLC reduced its position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 12.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 280,000 shares of the biotechnology compMay 4 at 7:14 AM | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Shares Acquired by MML Investors Services LLCMML Investors Services LLC increased its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 45.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 29,673 shares of the biotechnoloMay 4 at 3:54 AM | marketbeat.comResearch Analysts Set Expectations for VKTX FY2025 EarningsViking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Viking Therapeutics in a research report issued on Tuesday, April 29th. Cantor Fitzgerald analyst S. Seedhouse forecasts that the biotechnology companyMay 3, 2025 | marketbeat.comViking Therapeutics (NasdaqCM:VKTX) Reports Increased Net Loss of US$46 Million in Q1 2025May 3, 2025 | finance.yahoo.comWhy Viking Therapeutics Stock Was Victorious This WeekMay 2, 2025 | fool.comWhy Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped FridayMay 2, 2025 | fool.comViking Therapeutics (NASDAQ:VKTX) Raised to "Strong-Buy" at Cantor FitzgeraldCantor Fitzgerald upgraded Viking Therapeutics to a "strong-buy" rating in a report on Tuesday.May 2, 2025 | marketbeat.comWhere Will Viking Therapeutics Be in 3 Years?May 2, 2025 | fool.comTraders Purchase Large Volume of Viking Therapeutics Call Options (NASDAQ:VKTX)Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) saw unusually large options trading on Wednesday. Stock traders acquired 47,999 call options on the company. This represents an increase of approximately 189% compared to the average daily volume of 16,605 call options.May 2, 2025 | marketbeat.comBrokers Offer Predictions for VKTX FY2025 EarningsMay 2, 2025 | americanbankingnews.comViking Therapeutics (NASDAQ:VKTX) Shares Gap Up - What's Next?Viking Therapeutics (NASDAQ:VKTX) Shares Gap Up - Here's WhyMay 1, 2025 | marketbeat.com1 Beaten-Down Stock to Buy and Hold for 10 YearsMay 1, 2025 | fool.comStifel Financial Corp Increases Stock Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)Stifel Financial Corp grew its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 36.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 178,819 shares of the biotechnology company's stock after buying anMay 1, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Rating Increased to Strong-Buy at Cantor FitzgeraldMay 1, 2025 | americanbankingnews.comViking Therapeutics (NASDAQ:VKTX) Coverage Initiated by Analysts at Cantor FitzgeraldCantor Fitzgerald began coverage on Viking Therapeutics in a research report on Monday. They issued an "overweight" rating and a $104.00 price target for the company.April 30, 2025 | marketbeat.comTruist Financial Reiterates Buy Rating for Viking Therapeutics (NASDAQ:VKTX)Truist Financial reissued a "buy" rating and set a $75.00 price target (down from $95.00) on shares of Viking Therapeutics in a report on Monday.April 30, 2025 | marketbeat.comGilder Gagnon Howe & Co. LLC Takes $671,000 Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)Gilder Gagnon Howe & Co. LLC purchased a new position in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 16,678 shares of the bioteApril 30, 2025 | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Shares Sold by Voya Investment Management LLCVoya Investment Management LLC decreased its position in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 42.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 390,140 shares of the biotechnApril 30, 2025 | marketbeat.comViking Therapeutics, Inc. (NASDAQ:VKTX) Shares Bought by Barclays PLCBarclays PLC boosted its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 11.9% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 92,556 shares of the biotechnology company's stock after purchasing an additional 9,825 shares during tApril 30, 2025 | marketbeat.comPrediction: Pfizer's Loss May Be Viking Therapeutics' GainApril 30, 2025 | fool.comViking Therapeutics (NASDAQ:VKTX) Receives Buy Rating from Truist FinancialApril 30, 2025 | americanbankingnews.comCantor Fitzgerald Initiates Coverage of Viking Therapeutics (VKTX) with Overweight RecommendationApril 30, 2025 | msn.comWhy Viking Therapeutics Stock Popped Again TodayApril 29, 2025 | fool.comViking Therapeutics, Inc. (NASDAQ:VKTX) Shares Sold by Artia Global Partners LPArtia Global Partners LP lessened its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 83.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 90,279 shares of the biotechnology company's sApril 29, 2025 | marketbeat.comAquatic Capital Management LLC Purchases New Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)Aquatic Capital Management LLC purchased a new stake in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 209,134 shares of the biotechnology company's stock, valApril 29, 2025 | marketbeat.comWilliam Blair Analysts Lower Earnings Estimates for VKTXApril 29, 2025 | americanbankingnews.comQ2 EPS Forecast for Viking Therapeutics Decreased by AnalystApril 29, 2025 | americanbankingnews.comQ2 EPS Forecast for Viking Therapeutics Lowered by AnalystViking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) - Equities researchers at B. Riley dropped their Q2 2025 EPS estimates for shares of Viking Therapeutics in a note issued to investors on Thursday, April 24th. B. Riley analyst M. Mamtani now expects that the biotechnology company will post eaApril 29, 2025 | marketbeat.comHC Wainwright Has Pessimistic Outlook of VKTX Q2 EarningsViking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) - Equities researchers at HC Wainwright reduced their Q2 2025 earnings per share (EPS) estimates for Viking Therapeutics in a note issued to investors on Thursday, April 24th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnoApril 29, 2025 | marketbeat.comLeerink Partnrs Has Negative Estimate for VKTX Q2 EarningsViking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) - Analysts at Leerink Partnrs lowered their Q2 2025 earnings per share estimates for shares of Viking Therapeutics in a research report issued to clients and investors on Wednesday, April 23rd. Leerink Partnrs analyst T. Smith now forecasts thApril 29, 2025 | marketbeat.comWilliam Blair Issues Negative Estimate for VKTX EarningsViking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) - Stock analysts at William Blair decreased their Q2 2025 earnings per share (EPS) estimates for shares of Viking Therapeutics in a note issued to investors on Wednesday, April 23rd. William Blair analyst A. Hsieh now forecasts that the biotecApril 29, 2025 | marketbeat.comWhy Viking Therapeutics Stock Popped TodayApril 28, 2025 | fool.comQ2 EPS Estimate for Viking Therapeutics Lowered by AnalystApril 28, 2025 | americanbankingnews.comViking Therapeutics' (VKTX) Buy Rating Reiterated at HC WainwrightApril 27, 2025 | americanbankingnews.comResearch Analysts Offer Predictions for VKTX FY2029 EarningsViking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) - Leerink Partnrs reduced their FY2029 earnings estimates for Viking Therapeutics in a research report issued to clients and investors on Wednesday, April 23rd. Leerink Partnrs analyst T. Smith now expects that the biotechnology company will eApril 26, 2025 | marketbeat.comViking Therapeutics participates in a conference call with Maxim GroupApril 26, 2025 | markets.businessinsider.comViking Therapeutics (NASDAQ:VKTX) Given New $102.00 Price Target at Morgan StanleyMorgan Stanley dropped their target price on Viking Therapeutics from $105.00 to $102.00 and set an "overweight" rating on the stock in a report on Thursday.April 25, 2025 | marketbeat.comViking Therapeutics' (VKTX) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $102.00 price objective on shares of Viking Therapeutics in a research report on Thursday.April 25, 2025 | marketbeat.comViking Therapeutics Stock May Struggle After As-Expected ReportViking Therapeutics stock is trying to push higher as investors attempt to sort out a report that delivered no real news that investors hadn’t already heard.April 25, 2025 | marketbeat.comViking Therapeutics price target lowered to $85 from $96 at B. RileyApril 25, 2025 | markets.businessinsider.comHood River Capital Management LLC Sells 772,148 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)Hood River Capital Management LLC decreased its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 94.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 43,530 shares of theApril 25, 2025 | marketbeat.comJ. Safra Sarasin Holding AG Makes New $552,000 Investment in Viking Therapeutics, Inc. (NASDAQ:VKTX)J. Safra Sarasin Holding AG purchased a new stake in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund purchased 13,710 shares of the biotechnology company's stock, valued at approximately $552,000. A number of otherApril 25, 2025 | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Releases Earnings Results, Misses Expectations By $0.07 EPSViking Therapeutics (NASDAQ:VKTX - Get Free Report) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.07).April 24, 2025 | marketbeat.comScotiabank Keeps Their Buy Rating on Viking Therapeutics (VKTX)April 24, 2025 | markets.businessinsider.com Get Viking Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address VKTX Media Mentions By Week VKTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VKTX News Sentiment▼0.900.64▲Average Medical News Sentiment VKTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VKTX Articles This Week▼2417▲VKTX Articles Average Week Get Viking Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Dr. Reddy's Laboratories News Today Moderna News Today Ascendis Pharma A/S News Today Viatris News Today Qiagen News Today Roivant Sciences News Today Revolution Medicines News Today Lantheus News Today BridgeBio Pharma News Today Blueprint Medicines News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VKTX) was last updated on 5/7/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viking Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VKTX Stock Free VKTX Stock Alerts